Literature DB >> 20427809

Pancreatic cancer.

Manuel Hidalgo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20427809     DOI： 10.1056/NEJMra0901557

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  1172 in total

Review 1.  Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets.

Authors:  Matthias Drosten; Carmen Guerra; Mariano Barbacid
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

2.  A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer.

Authors:  J Rodríguez-Pascual; P Sha; E García-García; N V Rajeshkumar; E De Vicente; Y Quijano; A Cubillo; B Angulo; O Hernando; M Hidalgo
Journal:  Invest New Drugs       Date:  2012-06-07       Impact factor: 3.850

Review 3.  Biomarkers and molecular diagnosis of gastrointestinal and pancreatic neoplasms.

Authors:  Shelby D Melton; Robert M Genta; Rhonda F Souza
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-05       Impact factor: 46.802

4.  Targeted silencing of TRPM7 ion channel induces replicative senescence and produces enhanced cytotoxicity with gemcitabine in pancreatic adenocarcinoma.

Authors:  Nelson S Yee; Weiqiang Zhou; Minsun Lee; Rosemary K Yee
Journal:  Cancer Lett       Date:  2011-12-11       Impact factor: 8.679

5.  The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis.

Authors:  Viviane Palhares Muniz; J Matthew Barnes; Seema Paliwal; Xuefeng Zhang; Xiaoyun Tang; Songhai Chen; Kokou D Zamba; Joseph J Cullen; David K Meyerholz; Shari Meyers; J Nathan Davis; Steven R Grossman; Michael D Henry; Dawn E Quelle
Journal:  Mol Cancer Res       Date:  2011-06-02       Impact factor: 5.852

6.  Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers.

Authors:  Elad Sharon; Jingli Zhang; Kevin Hollevoet; Seth M Steinberg; Ira Pastan; Masanori Onda; Jochen Gaedcke; B Michael Ghadimi; Thomas Ried; Raffit Hassan
Journal:  Clin Chem Lab Med       Date:  2012-04       Impact factor: 3.694

7.  Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction.

Authors:  Xin Jin; Yunqian Pan; Liguo Wang; Tao Ma; Lizhi Zhang; Amy H Tang; Daniel D Billadeau; Heshui Wu; Haojie Huang
Journal:  Cancer Res       Date:  2017-07-18       Impact factor: 12.701

8.  Trojan-horse nanotube on-command intracellular drug delivery.

Authors:  Chia-Hsuan Wu; Cong Cao; Jin Ho Kim; Chih-Hsun Hsu; Harold J Wanebo; Wayne D Bowen; Jimmy Xu; John Marshall
Journal:  Nano Lett       Date:  2012-10-25       Impact factor: 11.189

9.  A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma.

Authors:  Zijian Yang; Michael J LaRiviere; Jina Ko; Jacob E Till; Theresa Christensen; Stephanie S Yee; Taylor A Black; Kyle Tien; Andrew Lin; Hanfei Shen; Neha Bhagwat; Daniel Herman; Andrew Adallah; Mark H O'Hara; Charles M Vollmer; Bryson W Katona; Ben Z Stanger; David Issadore; Erica L Carpenter
Journal:  Clin Cancer Res       Date:  2020-04-16       Impact factor: 12.531

Review 10.  Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review.

Authors:  Erkut Borazanci; Sherri Z Millis; Ron Korn; Haiyong Han; Clifford J Whatcott; Zoran Gatalica; Michael T Barrett; Derek Cridebring; Daniel D Von Hoff
Journal:  World J Gastrointest Oncol       Date:  2015-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.